Regenerative Case Studies — OriGen Clinics

Clinical Summaries (Pilot Series)

Regenerative ECM Case Studies

Expandable, clinic‑ready summaries you can share with patients. These are small pilot series (n=3 each) with 8‑week follow‑up. They indicate short‑term safety and symptomatic improvement; larger controlled studies are needed to confirm efficacy.

Back Knee Shoulder

Back

Safety & Early Efficacy of Perinatal‑Derived ECM for Lumbar Back Pain (n=3, 8 weeks)

Single ultrasound‑guided paraspinal injection • 3 mL ECM • No adverse events observed

8→4VAS (Pt 1, age 55)

6→2VAS (Pt 2, age 48)

7→3VAS (Pt 3, age 62)

What was done

Adults (35–70) with chronic lumbar pain >6 months and degenerative findings received a single 3 mL perinatal‑derived ECM injection into the paraspinal musculature under ultrasound guidance. Standard sterile technique and brief observation were used. Aftercare advised temporary activity modification and avoidance of NSAIDs/alcohol for 72 hours.

Outcomes at 8 weeks

Participant	Baseline VAS	8‑Week VAS	Reported Functional Change	Satisfaction
55 y/o	8	4	Improved mobility; less morning stiffness	Very satisfied
48 y/o	6	2	Better sitting tolerance; return to light exercise	Very satisfied
62 y/o	7	3	Improved daily function; reduced end‑of‑day pain	Satisfied

Why it may help

Perinatal‑derived ECM provides biologic scaffolding and bioactive signaling that may support tissue repair, modulate inflammation, and encourage angiogenesis, potentially improving the local environment for healing.

Potential adjacent applications (clinical context)

Facet‑related pain Discogenic pain (non‑surgical) Sacroiliac region symptoms Paraspinal myofascial pain

These are clinical contexts where similar mechanisms may be explored. Evidence is preliminary; patient selection and imaging correlation are important.

No adverse events were observed in this 3‑participant series through 8 weeks; findings are preliminary and hypothesis‑generating.

Full clinical write‑up (tap to open)

Knee

Perinatal‑Derived ECM Combination for Knee OA (EXO‑MOVE + ECM, n=3, 8 weeks)

Single ultrasound‑guided intra‑articular injection • 2 mL total (1 mL + 1 mL) • No adverse events observed

7→3VAS (Pt 1, KL III)

6→2VAS (Pt 2, KL II)

8→4VAS (Pt 3, KL II)

What was done

Adults 40–65 with symptomatic, radiographically confirmed Kellgren–Lawrence grade II–III OA received a single 2 mL ultrasound‑guided intra‑articular injection combining two perinatal‑derived ECM preparations. Aftercare included reduced knee loading for 2–3 days.

Outcomes at 8 weeks

Participant	KL Grade	Baseline VAS	8‑Week VAS	Reported Functional Change	Satisfaction
60 y/o	III	7	3	Longer walking distance; less stiffness; first time in years without daily pain	More than satisfied
40 y/o	II	6	2	Improved stair climbing; greater daily comfort	Very satisfied
65 y/o	II	8	4	Functional gains; some evening pain persisted	Very satisfied

Why a combination?

Blending complementary ECM preparations may pair structural scaffolding with bioactive signals for cellular attachment, remodeling, and inflammation modulation inside the joint.

Potential adjacent applications (clinical context)

Meniscal degeneration (non‑surgical) Patellofemoral pain Post‑arthroscopy recovery adjunct Ligamentous/soft‑tissue irritation

Contexts where joint‑level anti‑inflammatory and pro‑healing environments are clinically relevant. Evidence remains early‑stage.

No adverse events observed in this series; results suggest short‑term symptomatic benefit. Controlled trials with longer follow‑up are needed.

Full clinical write‑up (tap to open)

Shoulder

Perinatal‑Derived ECM Combination for Chronic Shoulder Pain (n=3, 8 weeks)

Single ultrasound‑guided intra‑ / peri‑articular injection • 2 mL total • No adverse events observed

7→2VAS (Pt 1)

6→3VAS (Pt 2)

8→2VAS (Pt 3)

What was done

Adults 35–70 with chronic shoulder pain (>6 months) and degenerative/inflammatory findings received a single 2 mL ultrasound‑guided injection combining intra‑articular and peri‑articular placement. Overhead activity was limited for 2–3 days post‑procedure.

Outcomes at 8 weeks

Participant	Baseline VAS	8‑Week VAS	Reported Functional Change	Satisfaction
50 y/o	7	2	Improved mobility; less night pain	Very satisfied
44 y/o	6	3	Better overhead tolerance; decreased stiffness	Very satisfied
61 y/o	8	2	Improved daily function; mild exertional pain remains	Satisfied

Why it may help

ECM‑based biologics may support rotator‑cuff and capsular tissue environments via scaffolding for cell attachment, pro‑angiogenic signaling, and inflammation modulation.

Potential adjacent applications (clinical context)

Rotator cuff tendinopathy Adhesive capsulitis (frozen shoulder) AC‑joint irritation Biceps tendon symptoms

Use‑cases where peri‑tendinous and capsular environments are targeted. Evidence base is evolving; individualized assessment is essential.

Across three participants, pain reductions and ROM/function gains were reported by 8 weeks with no adverse events noted.

Full clinical write‑up (tap to open)

What to know before you decide

These are small case groups (3 people each) without comparison groups. They are early snapshots to guide discussion—not final proof.
Fit matters. Imaging, your exam, and your goals help decide if this makes sense for you.
Expect brief soreness or swelling for a day or two. Avoid NSAIDs and alcohol for ~72 hours unless your clinician says otherwise.
Results vary. Some people feel better quickly; others need more time or a different plan.

This overview is educational and not medical advice. Please talk with your clinician to decide what’s right for you.